866940-27-4Relevant academic research and scientific papers
INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7)
-
Paragraph 154; 155, (2016/12/26)
The present invention provides novel compounds of Formula (I) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of cyclin-dependent kinase (e.g., CDK7), and therefore induce cellular apoptosis and/or inhibit transcription in the subject.
Design and sterospecific synthesis of modular ligands based upon cis-1,3-trans-5-substituted cyclohexanes
Fielden, John,Sprott, Joanna,Cronin, Leroy
, p. 1152 - 1158 (2007/10/03)
A range of eight novel ligands, based on the cis-1,3-trans-5-substituted cyclohexane framework, have been synthesized by a stereospecific route starting from cw-1,3,5-cyclohexanetriol. This route depends on the use of efficient mono-silylation and mono-to
